Get the Stockscreener App
110.39
9.41%
9.49
After Hours:
111.40
1.01
+0.91%
Abivax Adr stock is traded at $110.39, with a volume of 2.42M.
It is up +9.41% in the last 24 hours and up +12.85% over the past month.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
See More
Previous Close:
$100.90
Open:
$103
24h Volume:
2.42M
Relative Volume:
2.25
Market Cap:
$8.34B
Revenue:
-
Net Income/Loss:
$-159.39M
P/E Ratio:
-31.18
EPS:
-3.5401
Net Cash Flow:
$-105.22M
1W Performance:
+4.86%
1M Performance:
+12.85%
6M Performance:
+1,710%
1Y Performance:
+1,008%
1-Day Range:
$103.00
$112.50
1-Week Range:
$100.50
$112.50
52-Week Range:
$4.77
$112.50
Abivax Adr Stock (ABVX) Company Profile
Compare ABVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
110.39 | 7.85B | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Initiated | Wolfe Research | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jul-23-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-20-25 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | Laidlaw | Buy |
| May-20-24 | Initiated | BTIG Research | Buy |
| Apr-29-24 | Initiated | Guggenheim | Buy |
| Apr-29-24 | Initiated | Piper Sandler | Overweight |
| Nov-14-23 | Initiated | Leerink Partners | Outperform |
| Nov-14-23 | Initiated | Morgan Stanley | Equal-Weight |
View All
Abivax Adr Stock (ABVX) Latest News
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
A new trading data show Abivax ADR (ABVX) is showing positive returns. - setenews.com
Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year? - Yahoo Finance
Abivax (NASDAQ:ABVX) Sets New 52-Week HighShould You Buy? - MarketBeat
Get in on Abivax ADR’s (ABVX) buy-in window today! - setenews.com
Positive Outlook for Abivax SA: Obefazimod’s Potential in Crohn’s Disease Drives Buy Rating - TipRanks
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Abivax (NASDAQ:ABVX) Sets New 12-Month HighShould You Buy? - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Decrease in Short Interest - MarketBeat
ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
Leerink Partnrs Analysts Raise Earnings Estimates for Abivax - Defense World
Abivax SA Sponsored ADR (ABVX) Receives a Rating Update from a Top Analyst - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Abivax Shares Surge After Strong Phase 3 Results in Ulcerative Colitis Study - MSN
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data - GlobeNewswire Inc.
FY2025 EPS Estimates for Abivax Boosted by Lifesci Capital - Defense World
Abivax SA Reports Financial Results and Strategic Advances - MSN
Abivax Reports Increased Losses but Secures Major Funding in H1 2025 - msn.com
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 42.1% in August - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Increase in Short Interest - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $95.14 Consensus PT from Brokerages - MarketBeat
Abivax (NASDAQ:ABVX) Shares Gap Down – What’s Next? - Defense World
Octagon Capital Advisors LP Makes New $7.69 Million Investment in Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Down 38.0% in August - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Buy” by Brokerages - Defense World
Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season - FinancialContent
Abivax SA Sponsored ADR $ABVX Stock Position Increased by ADAR1 Capital Management LLC - MarketBeat
Paloma Partners Management Co Purchases Shares of 38,449 Abivax SA Sponsored ADR $ABVX - MarketBeat
Nantahala Capital Management LLC Has $9.27 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX - MarketBeat
Walleye Capital LLC Has $1.38 Million Stock Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Affinity Asset Advisors LLC Takes $1.25 Million Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Analysts Bullish on Healthcare Stocks: Labcorp Holdings and Abivax SA Sponsored ADR - AInvest
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 12-Month High – What’s Next? - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 28.7% in July - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Analysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Target Price at $92.33 - Defense World
Abivax (NASDAQ:ABVX) Stock Price Up 5.2% on Analyst Upgrade - Defense World
Leerink Partnrs Brokers Reduce Earnings Estimates for Abivax - Defense World
Lifesci Capital Brokers Lift Earnings Estimates for Abivax - Defense World
Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $78.75 - Defense World
Abivax SA Announces $608.6 Million Public Offering of ADSs - The Globe and Mail
Abivax (NASDAQ:ABVX) Reaches New 52-Week High on Analyst Upgrade - Defense World
Abivax SA Stock Surges on Promising Drug Results - TipRanks
Abivax (NASDAQ:ABVX) Trading 577.5% Higher on Analyst Upgrade - Defense World
Abivax Adr Stock (ABVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):